RespireRx Pharmaceuticals Inc. Annual Operating Income (Loss) in USD from 2010 to 2022

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
RespireRx Pharmaceuticals Inc. quarterly/annual Operating Income (Loss) history and growth rate from 2010 to 2022.
  • RespireRx Pharmaceuticals Inc. Operating Income (Loss) for the quarter ending September 30, 2023 was -$333K, a 14.5% increase year-over-year.
  • RespireRx Pharmaceuticals Inc. Operating Income (Loss) for the twelve months ending September 30, 2023 was -$1.41M, a 24.7% increase year-over-year.
  • RespireRx Pharmaceuticals Inc. annual Operating Income (Loss) for 2022 was -$1.58M, a 38.3% increase from 2021.
  • RespireRx Pharmaceuticals Inc. annual Operating Income (Loss) for 2021 was -$2.56M, a 22.8% increase from 2020.
  • RespireRx Pharmaceuticals Inc. annual Operating Income (Loss) for 2020 was -$3.32M, a 90.9% decline from 2019.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Annual (USD)
Operating Income (Loss), YoY Annual Growth (%)
* An asterisk sign (*) next to the value indicates that the value is likely invalid.